P2Y14R antagonist 1

P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3) /gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis[1].

Product Specifications

CAS Number

[2728291-29-8]

UNSPSC

12352005

Target

NOD-like Receptor (NLR) ; P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/p2y14r-antagonist-1.html

Purity

98.76

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC2=C(C=C1)N=CN2)COC3=CC=C(C=C3)Br

Molecular Formula

C15H12BrN3O2

Molecular Weight

346.18

References & Citations

[1]Liu W, et al. Discovery of N-Substituted Acetamide Derivatives as Promising P2Y14R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay. J Med Chem. 2024 Jun 27;67 (12) :10233-10247.